Dashboard
Manage Tickers

NSPR


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

inspiremd-has-submitted-a-premarket-approval-application-to-fda-seeking-approval-for-the-cguard-prime-carotid-stent-system-us-commercial-launch-anticipated-in-h1-2025-if-approved
InspireMD Has Submitted A Premarket Approv...
09/16/2024 11:05:32

inspiremd-q2-2024-gaap-eps-022-misses-020-estimate-sales-1739m-miss-1740m-estimate
InspireMD Q2 2024 GAAP EPS $(0.22) Misses ...
08/06/2024 10:15:25

inspiremd-presents-one-year-follow-up-results-from-c-guardians-us-ide-trial-of-cguard-at-linc-2024-on-may-28-at-853-am-edt
InspireMD Presents One-Year Follow-Up Resu...
05/28/2024 12:56:08

inspiremd-q1-2024-gaap-eps-021-misses-015-estimate-sales-1511b-beat-1384m-estimate
InspireMD Q1 2024 GAAP EPS $(0.21) Misses ...
05/14/2024 10:27:28

InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) b...

inspiremd-announces-abstract-of-one-year-follow-up-results-from-c-guardians-us-investigational-device-exemption-clinical-trial-accepted-for-presentation-at-linc-2024
InspireMD Announces Abstract Of One-year F...
03/26/2024 11:13:59

inspiremd-q4-eps-016-beats-020-estimate-sales-176m-beat-163m-estimate
InspireMD Q4 EPS $(0.16) Beats $(0.20) Est...
03/06/2024 12:01:21

InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by ...

earnings-scheduled-for-march-6-2024
Earnings Scheduled For March 6, 2024
03/06/2024 10:00:02

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...

preview-inspiremds-earnings
Preview: InspireMD's Earnings
03/05/2024 19:02:55

inspiremd-appoints-principal-investigators-for-its-upcoming-c-guardians-ii-clinical-trial-of-switchguard-neuroprotection-system
InspireMD Appoints Principal Investigators...
02/12/2024 12:05:22

inspiremd-receives-ce-mark-recertification-under-eus-new-medical-device-regulation-mdr-regulatory-framework
InspireMD Receives CE Mark Recertification...
01/31/2024 12:05:59

inspiremd-reveals-issuance-of-key-us-patent-covering-its-switchguard-neuroprotection-system
InspireMD Reveals Issuance Of Key U.S. Pat...
12/20/2023 12:02:13

inspiremd-enters-into-an-agreement-with-jacobs-institute-at-the-state-university-of-new-york-for-an-early-feasibility-study-of-cguard-eps-carotid-stent-in-conjunction-with-thrombectomy-in-patients-with-acute-ischemic-stroke-and-tandem-lesions
InspireMD Enters Into An Agreement With Ja...
11/27/2023 12:08:37

earnings-scheduled-for-november-6-2023
Earnings Scheduled For November 6, 2023
11/06/2023 13:24:53

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on ...

inspiremd-sold-2734-cguard-eps-stent-systems-in-q3-compared-to-2624-a-year-ago
InspireMD Sold 2,734 CGuard EPS Stent Syst...
11/06/2023 12:06:46

inspiremd-q3-eps-015-inline-sales-156m-beat-150m-estimate
InspireMD Q3 EPS $(0.15), Inline, Sales $1...
11/06/2023 12:04:36

InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 74.1...

inspiremd-earnings-preview
InspireMD Earnings Preview
11/03/2023 20:01:50

piper-sandler-maintains-overweight-on-inspiremd-raises-price-target-to-45
Piper Sandler Maintains Overweight on Insp...
11/02/2023 19:58:27

Piper Sandler analyst Adam Maeder maintains InspireMD (NASDAQ:NSPR) with a Overweight and raises the price target from $3.5 ...

inspiremd-presents-30-day-follow-up-results-from-the-c-guardians-us-investigational-device-exemption-clinical-trial-at-viva23
InspireMD Presents 30-Day Follow-Up Result...
11/01/2023 18:26:38

InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, tod...

inspiremd-announced-its-support-for-centers-for-medicare--medicaid-services-final-national-coverage-determination-which-expands-coverage-of-carotid-artery-stenting-and-transcarotid-artery-revascularization-to-include-asymptomatic--standard-risk-patients
InspireMD Announced Its Support For Center...
10/12/2023 11:29:36

inspiremd-announces-abstract-of-30-day-results-from-the-c-guardians-us-investigational-device-exemption-clinical-trial-accepted-for-presentation-at-viva23
InspireMD Announces Abstract Of 30-Day Res...
08/31/2023 12:07:28

InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, tod...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION